MA41962A - Récepteur antigénique chimérique ciblant le cd5 pour une thérapie adoptive à base de cellules t - Google Patents

Récepteur antigénique chimérique ciblant le cd5 pour une thérapie adoptive à base de cellules t

Info

Publication number
MA41962A
MA41962A MA041962A MA41962A MA41962A MA 41962 A MA41962 A MA 41962A MA 041962 A MA041962 A MA 041962A MA 41962 A MA41962 A MA 41962A MA 41962 A MA41962 A MA 41962A
Authority
MA
Morocco
Prior art keywords
chemerical
adoptive
cell therapy
receptor targeting
antigenic receptor
Prior art date
Application number
MA041962A
Other languages
English (en)
Inventor
Malcolm K Brenner
Maksim Mamonkin
Original Assignee
Baylor College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College Medicine filed Critical Baylor College Medicine
Publication of MA41962A publication Critical patent/MA41962A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/17—Hinge-spacer domain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
MA041962A 2015-04-23 2016-04-22 Récepteur antigénique chimérique ciblant le cd5 pour une thérapie adoptive à base de cellules t MA41962A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562151609P 2015-04-23 2015-04-23

Publications (1)

Publication Number Publication Date
MA41962A true MA41962A (fr) 2018-02-28

Family

ID=57144257

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041962A MA41962A (fr) 2015-04-23 2016-04-22 Récepteur antigénique chimérique ciblant le cd5 pour une thérapie adoptive à base de cellules t

Country Status (4)

Country Link
US (2) US10786549B2 (fr)
EP (1) EP3286225B1 (fr)
MA (1) MA41962A (fr)
WO (1) WO2016172606A1 (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017008042A2 (pt) 2014-10-20 2017-12-26 Juno Therapeutics Inc métodos e composições para dosagem em terapia de célula adotiva
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
JP7237449B2 (ja) * 2015-02-27 2023-03-13 アイセル・ジーン・セラピューティクス・エルエルシー 血液系腫瘍を標的としたキメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
EP3286225B1 (fr) * 2015-04-23 2020-07-01 Baylor College of Medicine Récepteur antigénique chimérique ciblant le cd5 pour une thérapie adoptive à base de cellules t
GB201518816D0 (en) 2015-10-23 2015-12-09 Autolus Ltd Receptor
NZ750256A (en) 2016-08-03 2026-02-27 Dipersio John F Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
GB201622044D0 (en) * 2016-12-22 2017-02-08 Ucl Business Plc T cell-targeted T cells
US12163952B2 (en) 2017-02-27 2024-12-10 Juno Therapeutics, Inc. Determining toxicity risk in CAR T-cell therapy
WO2018195339A1 (fr) 2017-04-19 2018-10-25 Board Of Regents, The University Of Texas System Cellules immunitaires exprimant des récepteurs d'antigènes modifiés
AU2018275894B2 (en) * 2017-06-02 2025-04-24 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
JP2020525537A (ja) * 2017-06-12 2020-08-27 エモリー ユニバーシティー Ｔ細胞抗原標的キメラ抗原受容体（ｃａｒ）、及び細胞療法での使用
CN111432823A (zh) * 2017-07-25 2020-07-17 得克萨斯大学体系董事会 增强的嵌合抗原受体及其用途
WO2019089858A2 (fr) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Procédés d'évaluation ou de surveillance d'une réponse à une thérapie cellulaire
EP3704230B1 (fr) 2017-11-01 2024-10-23 Juno Therapeutics, Inc. Procédé de génération de compositions thérapeutiques de cellules modifiées
WO2019108863A1 (fr) 2017-11-29 2019-06-06 Magenta Therapeutics, Inc. Compositions et procédés pour la déplétion des cellules cd5+
EP3720950B1 (fr) * 2017-12-05 2025-09-03 Celyad S.A. Réduction de fratricide de cellules immunitaires exprimant des récepteurs à base de nkg2d
CA3084446A1 (fr) 2017-12-08 2019-06-13 Juno Therapeutics, Inc. Marqueurs phenotypiques pour therapie cellulaire et procedes associes
EP3765054A4 (fr) * 2018-01-19 2022-01-12 The Trustees Of The University Of Pennsylvania Compositions et méthodes de ciblage de lymphocytes t gamma delta au moyen de récepteurs antigéniques chimériques
JP7273421B2 (ja) 2018-02-21 2023-05-15 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用
US20210236548A1 (en) * 2018-04-20 2021-08-05 The Regents Of The University Of California Treatment of prostate cancer using chimeric antigen receptors
EP3876977A1 (fr) 2018-11-06 2021-09-15 The Regents Of The University Of California Récepteurs antigéniques chimériques pour la phagocytose
WO2020142780A1 (fr) * 2019-01-06 2020-07-09 Tocagen Inc. Méthodes et constructions de lymphocytes t car
SG11202110287QA (en) 2019-04-24 2021-10-28 Heidelberg Pharma Res Gmbh Amatoxin antibody-drug conjugates and uses thereof
CA3135531A1 (fr) * 2019-04-30 2020-11-05 Daniel Getts Compositions de proteines de fusion chimeriques modifiees et leurs procedes d'utilisation
US11013764B2 (en) 2019-04-30 2021-05-25 Myeloid Therapeutics, Inc. Engineered phagocytic receptor compositions and methods of use thereof
CA3138991A1 (fr) * 2019-05-02 2020-11-05 Ligandal, Inc. Methodes et compositions pour l'administration d'agents therapeutiques ciblee sur des ligands, sensible au diagnostic
JP7831937B2 (ja) 2019-09-03 2026-03-17 クリエイト・メディシンズ，インコーポレーテッド ゲノム組込みのための方法および組成物
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
CN116568709A (zh) * 2020-11-01 2023-08-08 南京驯鹿生物技术股份有限公司 靶向cd5的全人源抗体、全人源嵌合抗原受体（car）及其应用
CA3197423A1 (fr) 2020-11-04 2022-05-12 Daniel Getts Compositions de proteines de fusion chimeriques modifiees et leurs procedes d'utilisation
US20240000838A1 (en) * 2020-11-30 2024-01-04 Simcere Innovation, Inc. Universal chimeric antigen receptor-expressing immune cells for allogeneic cell therapy
EP4279515A4 (fr) * 2021-01-12 2025-02-19 Nanjing Iaso Biotechnology Co., Ltd. Récepteur antigénique chimérique (car) à domaine unique en tandem entièrement humain ciblant cd5 et son utilisation
US20240101673A1 (en) 2021-02-03 2024-03-28 Mozart Therapeutics, Inc. Binding agents and methods of using the same
EP4308133A4 (fr) 2021-03-17 2025-01-22 Myeloid Therapeutics, Inc. Compositions de protéines de fusion chimériques modifiées et leurs méthodes d'utilisation
KR20240007911A (ko) * 2021-04-14 2024-01-17 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 Cd5-양성 암을 표적화하기 위한 키메라 항원 수용체
EP4326293A4 (fr) * 2021-04-22 2025-03-12 Baylor College of Medicine Procédés de modification de cellules immunitaires ayant une activité fratricide réduite
KR102831183B1 (ko) * 2021-04-29 2025-07-09 한국생명공학연구원 신규한 항-cd5 키메릭 항원 수용체 및 이를 발현하는 면역세포
AU2022272235A1 (en) 2021-05-11 2023-12-21 Create Medicines, Inc. Methods and compositions for genomic integration
WO2023076876A1 (fr) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation de réponses immunitaires à des vecteurs viraux
JP2024545574A (ja) * 2021-11-10 2024-12-10 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 神経変性障害の治療のための操作されたキメラ抗原受容体（ｃａｒ）ミクログリア様細胞
KR20250024750A (ko) * 2022-04-13 2025-02-19 티크바 알로셀 피티이. 엘티디. 치료용 t 세포 산물
WO2025129158A1 (fr) 2023-12-15 2025-06-19 The Broad Institute, Inc. Vésicules d'administration contenant des polypeptides arc modifiés et leurs utilisations

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
MX2011000970A (es) * 2008-08-29 2011-03-15 Symphogen As Anticuerpos anti-cd5.
JP6850528B2 (ja) 2012-02-13 2021-03-31 シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート 二重特異性キメラ抗原受容体およびその治療的使用
AU2013327136A1 (en) * 2012-10-02 2015-04-16 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
US20160296562A1 (en) 2013-11-21 2016-10-13 Ucl Business Plc Cell
JP7237449B2 (ja) * 2015-02-27 2023-03-13 アイセル・ジーン・セラピューティクス・エルエルシー 血液系腫瘍を標的としたキメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
EP3286225B1 (fr) * 2015-04-23 2020-07-01 Baylor College of Medicine Récepteur antigénique chimérique ciblant le cd5 pour une thérapie adoptive à base de cellules t
WO2017112877A1 (fr) 2015-12-22 2017-06-29 Icell Gene Therapeutics, Llc Récepteurs antigéniques chimériques et amélioration de l'activité anti-tumorale

Also Published As

Publication number Publication date
WO2016172606A1 (fr) 2016-10-27
EP3286225B1 (fr) 2020-07-01
US20180104308A1 (en) 2018-04-19
US20200405811A1 (en) 2020-12-31
EP3286225A1 (fr) 2018-02-28
US10786549B2 (en) 2020-09-29
EP3286225A4 (fr) 2018-10-10

Similar Documents

Publication Publication Date Title
MA41962A (fr) Récepteur antigénique chimérique ciblant le cd5 pour une thérapie adoptive à base de cellules t
IL284172A (en) Diagnostic methods for t cell therapy
IL263896A (en) T cell compositions for immunotherapy
EP3389677C0 (fr) Disruption ciblée du récepteur des lymphocytes t
PT3494133T (pt) Recetores de células t anti-kras-g12d
IL253627B (en) Predicting t cell epitopes useful for vaccination
DK3440106T3 (da) T-cellereceptorer
DK3440105T3 (da) T-cellereceptorer
IL256177A (en) T cell receptor like antibodies having fine specificity
MA43382A (fr) Modulateurs des récepteurs des chimiokines
BR112017012502A2 (pt) receptor quimérico de antígeno bcma
BR112017005630A2 (pt) células t de memória central para terapia adotiva com células t
IL255005A0 (en) Hepatic arterial infusion of car-t cells
EP3304511A4 (fr) Appareil de soutien de patient
IL249313A0 (en) Improved t cell compositions
IL250362B (en) Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
EP3442405A4 (fr) Ensemble de berceau ajustable
DK3394094T3 (da) T-celle receptorer specifikke for ny-eso-1 tumor antigen-hla-a*02 komplekset
DK3708579T3 (da) Claudin-6-specifikke immunreceptorer og t-celleepitoper
EP3352850A4 (fr) Appareil pour fournir une photothérapie
IL274025A (en) A new T-cell receptor
DK3433280T3 (da) Protease-aktiverede T-celle-bispecifikke molekyler
DK3490986T3 (da) Piperidin-cxcr7-receptormodulatorer
IL269629A (en) Treatment using chimeric receptor t cells incorporating optimized polyfunctional t cells
EP3592839C0 (fr) Récepteurs de cellules t restreints mr1 pour immunothérapie du cancer